COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory
-
- Andrew M. Borman
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Michael D. Palmer
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Mark Fraser
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Zoe Patterson
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Ciara Mann
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Debra Oliver
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Christopher J. Linton
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Martin Gough
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Phillipa Brown
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Agnieszka Dzietczyk
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Michelle Hedley
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Sue McLachlan
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Julie King
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Elizabeth M. Johnson
- UK National Mycology Reference Laboratory, Public Health England South-West, Bristol, United Kingdom
-
- Kimberly E. Hanson
- editor
説明
<jats:p>COVID-19-associated pulmonary aspergillosis (CAPA) was recently reported as a potential infective complication affecting critically ill patients with acute respiratory distress syndrome following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with incidence rates varying from 8 to 33% depending on the study. However, definitive diagnosis of CAPA is challenging. Standardized diagnostic algorithms and definitions are lacking, clinicians are reticent to perform aerosol-generating bronchoalveolar lavages for galactomannan testing and microscopic and cultural examination, and questions surround the diagnostic sensitivity of different serum biomarkers.</jats:p>
収録刊行物
-
- Journal of Clinical Microbiology
-
Journal of Clinical Microbiology 59 (1), 2020-12-17
American Society for Microbiology